Open Orphan has said that its hVIVO subsidiary has landed a £7.3 million influenza challenge study.
Under the terms of this agreement, the company researchers will carry out a double-blind, placebo, controlled assessment of the drug, which means one cohort will receive the active treatment, while the other half will be administered a substance with no medicinal value.
The scientists will analyse the drug’s potential to ward off the flu virus (its prophylactic properties) and the post-inoculation activity of the drug in healthy volunteers.